Tenpoint Therapeutics™ is advancing a pipeline of innovative therapies for common age-related eye diseases, including presbyopia, cataracts, and geographic atrophy (GA).
A dual-agent eye drop for presbyopia
A small-molecule injectable for cataracts
A regenerative cell replacement therapy for geographic atrophy
Tenpoint Therapeutics™ partners with eye care professionals to create innovative therapies designed to improve or restore vision and support long-term eye health.
Tenpoint Therapeutics™ Investigational Pipeline
| PROGRAM | DISEASE | OPPORTUNITY | SOLUTION | PHASE | KEY MILESTONES |
|---|---|---|---|---|---|
| BRIMOCHOL™ PF | Presbyopia | Being investigated to treat age-related near-vision loss | A multi-modal combination eye drop (carbachol and brimonidine tartrate) designed to produce a pinhole effect that may help sharpen near vision |
Phase III
|
|
| TPT-161 | Presbyopia/ Cataract | Being investigated to disrupt the Dysfunctional Lens Syndrome (DLS) continuum with a nonsurgical, natural lens health approach | A multi-targeted NCE that may treat and reverse lens protein aggregation and restores lens flexibility and clarity |
Preclinical
|
|
| TPT-005 | Geographic atrophy | Being investigated to restore vision where cells do not naturally regenerate | Investigational subretinal cell therapy that may restore vision in people that are affected by geographic atrophy |
Preclinical
|
|
NCE=new chemical entity; NDA=New Drug Application.
These two ingredients may help reduce pupil size, sharpen near vision, and minimize side effects by limiting peripheral light.1-4
Presbyopia drops work through two key mechanisms: constricting the pupil to extend depth of focus and engaging the ciliary muscle to support accommodation and regulate pupil size.5
Carbachol is a potent, long-lasting miotic agent that constricts the pupil, while brimonidine tartrate is an alpha-2 adrenergic agonist that inhibits the iris dilator muscle and prevents pupil dilation, offering the potential of5:
Understand the prevalence, burden, and treatment of presbyopia
It combines an alpha-crystallin chaperone with a reducing agent to6:
Alpha-crystallins are proteins that help maintain lens transparency by preventing other proteins from clumping. With age, they destabilize—making them key molecular targets in both presbyopia and cataracts.7–9
Over 2 billion people experience presbyopia, and hundreds of millions also develop cataracts. These two
conditions are part of dysfunctional lens syndrome (DLS)—a
progressive lens condition that begins with loss of
accommodation and may result in vision loss or blindness.10–12
Cataracts are caused by
Delivered via subretinal injection, it aims to replace lost retinal cells and help restore vision in advanced dry age-related macular degeneration (AMD).15
Geographic atrophy is characterized by irreversible vision loss due to the degeneration of retinal pigment epithelium (RPE) cells and photoreceptors. TPT‑005’s cell-based therapy is designed to restore vision by replacing RPE cells and support photoreceptors.15-17
GA is a late-stage form of dry AMD that causes irreversible damage to the retina and central vision. It’s a leading cause of vision loss in older adults, affecting 5 million people globally and 1 million in the U.S.16,18
GA is caused by
References: 1. VT-003 Clinical Study Report. Visus Therapeutics; May 21, 2025. 2. Abdelkader A. Efficacy of a fixed combination of brimonidine and carbachol in reducing physiological pupil dilation: potential for presbyopia therapy. Eye Contact Lens. 2015;41(6):323–327. 3. Abdelkader A. Combined versus separate carbachol and brimonidine therapy for presbyopia. Eye Vis (Lond). 2016;3:31. 4. VT-002 Clinical Study Report. Visus Therapeutics; October 5, 2023. 5. Integrated Summary of Safety (ISS). Visus Therapeutics; 2025. 6. Tenpoint Therapeutics. Data on file. 7. Molnar A, Ma J, Ghosh A, et al. Development of a pharmacological chaperone for α-crystallin and its potential for treating cataracts. Invest Ophthalmol Vis Sci. 2019;60(10):3320–3331. 8. Makley LN, McMenimen KA, DeVree BT, et al. Pharmacological chaperone for α-crystallin partially restores transparency in cataract models. Science. 2015;350(6261):674–677. 9. Wang AL, Haruta M, Wang Y, et al. Pharmacological targeting of α-crystallin with VP1-001 improves lens transparency in models of cataract. Invest Ophthalmol Vis Sci. 2022;63(5):15. 10. Lin L, Liang Y, Jiang G, Gan Q, Yang T, Liao P, et al. Global, regional, and national burden of cataract: a comprehensive analysis and projections from 1990 to 2021. PLOS One. 2025;20(6):e0326263. 11. Martínez-Plaza E, Pinilla I, Sánchez-Cano A. Dysfunctional lens syndrome: current concepts and clinical applications. Diagnostics (Basel). 2022;12(5):1167. 12. World Health Organization. Blindness and vision impairment. Updated August 10, 2023. Accessed September 4, 2025. https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment 13. Koetting J. Presbyopia and cataracts: dysfunctional lens syndrome. Optometry Times. 2023. Accessed September 4, 2025. https://www.optometrytimes.com/view/presbyopia-and-cataracts-dysfunctional-lens-syndrome 14. de Diego-García L, Gómez-Benlloch A, Pinazo-Durán MD. Pharmacological strategies for cataract management: from molecular targets to clinical translation. Int J Mol Sci. 2025;26(12):5658. 15. Tenpoint Therapeutics. Data on file. 16. Bakri SJ, Gaudana R, Ambati BK. Geographic atrophy: mechanisms of disease and emerging therapies. Am J Ophthalmol. 2023;250:16–28. 17. Li M, Huisingh CE, Messinger JD, et al. Histology of geographic atrophy secondary to age-related macular degeneration: a multilayer approach. Retina. 2018;38(10):1937–1953. 18. Saundankar V, Keane PA, Sadda SR. Emerging therapies for geographic atrophy secondary to age-related macular degeneration. Eye (Lond). 2023;37(7):1312–1325.
